Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
Neurocrine Biosciences (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, has announced its participation in four major investor conferences this September. The company's leadership team, including CEO Kyle Gano, CFO Matt Abernethy, and other executives, will present at the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference, and TD Cowen Novel Mechanisms Summit.
The presentations will be accessible via live webcasts on Neurocrine's website, with replays available for approximately one month. The company specializes in developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders, with FDA-approved treatments for conditions including tardive dyskinesia, Huntington's disease chorea, and endometriosis.
Neurocrine Biosciences (Nasdaq: NBIX), azienda biofarmaceutica focalizzata sulle neuroscienze, ha annunciato la partecipazione a quattro importanti conferenze per investitori questo settembre. Il team dirigente, guidato dall'amministratore delegato Kyle Gano e dal direttore finanziario Matt Abernethy, insieme ad altri dirigenti, presenter脿 al Cantor Global Healthcare Conference, al Morgan Stanley Global Healthcare Conference, al Baird Global Healthcare Conference e al TD Cowen Novel Mechanisms Summit.
Le presentazioni saranno trasmesse in diretta via webcast sul sito di Neurocrine, con replay disponibili per circa un mese. L'azienda 猫 specializzata nello sviluppo di terapie per disturbi neurologici, neuroendocrini e neuropsichiatrici e dispone di terapie approvate dalla FDA per condizioni quali la discinesia tardiva, la corea di Huntington e l'endometriosi.
Neurocrine Biosciences (Nasdaq: NBIX), una empresa biofarmac茅utica centrada en neurociencia, ha anunciado su participaci贸n en cuatro importantes conferencias para inversores este septiembre. El equipo directivo, encabezado por el CEO Kyle Gano y el CFO Matt Abernethy, junto con otros ejecutivos, presentar谩 en el Cantor Global Healthcare Conference, el Morgan Stanley Global Healthcare Conference, el Baird Global Healthcare Conference y el TD Cowen Novel Mechanisms Summit.
Las presentaciones se podr谩n seguir mediante webcasts en vivo en la p谩gina web de Neurocrine, con reproducciones disponibles durante aproximadamente un mes. La compa帽铆a se especializa en desarrollar tratamientos para trastornos neurol贸gicos, neuroendocrinos y neuropsiqui谩tricos, y tiene terapias aprobadas por la FDA para afecciones como la discinesia tard铆a, la corea de Huntington y la endometriosis.
Neurocrine Biosciences (雮橃姢雼�: NBIX)電� 鞁犼步瓿柬暀 欷戩嫭鞚� 欤检殧 氚旍澊鞓れ牅鞎届偓搿�, 鞚措矆 9鞗� 雱� 瓿踌潣 欤检殧 韴瀽鞛� 旎嵓霟办姢鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. CEO 旒�鞚茧Μ 瓴岇澊雲�(Kyle Gano), CFO 毵ろ姼 鞎犽矂雱れ嫓(Matt Abernethy) 霌� 瓴届榿歆勳澊 Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference 氚� TD Cowen Novel Mechanisms Summit鞐愳劀 氚滍憸頃� 鞓堨爼鞛呺媹雼�.
氚滍憸電� Neurocrine 鞗轨偓鞚错姼毳� 韱淀暅 霛检澊敫� 鞗轨簮鞀ろ姼搿� 鞁滌箔頃� 靾� 鞛堨溂氅�, 鞛儩 鞓侅儊鞚� 鞎� 頃� 雼皠 鞝滉车霅╇媹雼�. 鞚� 須岇偓電� 鞁犼步瓿�, 鞁犼步雮措秳牍勱硠 氚� 鞁犼步鞝曥嫚瓿检爜 歆堩櫂 旃橂鞝� 臧滊皽鞚� 鞝勲鞙茧 頃橂┌, 歆�鞐办劚 鞖措彊鞛レ暊(毵愳磮歃� 韽暔), 項岉寘韯措硲 氍措弰歃�, 鞛愱秮雮措歃� 霌� FDA 鞀轨澑 旃橂鞝滊ゼ 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
Neurocrine Biosciences (Nasdaq: NBIX), une soci茅t茅 biopharmaceutique ax茅e sur les neurosciences, a annonc茅 sa participation 脿 quatre grandes conf茅rences investisseurs en septembre. L'茅quipe dirigeante, incluant le PDG Kyle Gano, le directeur financier Matt Abernethy et d'autres cadres, pr茅sentera au Cantor Global Healthcare Conference, au Morgan Stanley Global Healthcare Conference, au Baird Global Healthcare Conference et au TD Cowen Novel Mechanisms Summit.
Les pr茅sentations seront accessibles via des webcasts en direct sur le site de Neurocrine, avec des replays disponibles pendant environ un mois. La soci茅t茅 est sp茅cialis茅e dans le d茅veloppement de traitements pour les troubles neurologiques, neuroendocriniens et neuropsychiatriques, et dispose de traitements approuv茅s par la FDA pour des affections telles que la dyskin茅sie tardive, la chor茅e de Huntington et l'endom茅triose.
Neurocrine Biosciences (Nasdaq: NBIX), ein auf Neurowissenschaften spezialisiertes biopharmazeutisches Unternehmen, hat seine Teilnahme an vier gro脽en Investorenkonferenzen im September angek眉ndigt. Das F眉hrungsteam, darunter CEO Kyle Gano und CFO Matt Abernethy sowie weitere F眉hrungskr盲fte, wird beim Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird Global Healthcare Conference und TD Cowen Novel Mechanisms Summit 辫谤盲蝉别苍迟颈别谤别苍.
Die Pr盲sentationen werden als Live-Webcasts auf der Neurocrine-Website verf眉gbar sein; Wiedergaben stehen f眉r etwa einen Monat zur Verf眉gung. Das Unternehmen spezialisiert sich auf die Entwicklung von Therapien f眉r neurologische, neuroendokrine und neuropsychiatrische Erkrankungen und verf眉gt 眉ber von der FDA zugelassene Behandlungen f眉r Erkrankungen wie tardive Dyskinesie, Chorea bei Huntington und Endometriose.
- None.
- None.
- Chief Financial Officer Matt Abernethy, Chief Commercial Officer Eric Benevich, and Vice-President of Investor Relations Todd Tushla will present at the Cantor Global Healthcare Conference 2025 at 1:00 p.m. ET on Wednesday, September 3, 2025.
- Chief Executive Officer Kyle Gano and Chief Medical Officer Sanjay Keswani will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 10:45 a.m. ET on Tuesday, September 9, 2025.
- Chief Executive Officer Kyle Gano, Chief Medical Officer Sanjay Keswani, and Vice-President of Investor Relations Todd Tushla will present at the Baird 2025 Global Healthcare Conference at 10:15 a.m. ET on Wednesday, September 10, 2025.
- Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla will present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry and Epilepsy Virtual Summit at 12:40 p.m. ET on Wednesday, September 17, 2025.
The live webcasts can be accessed on Neurocrine Biosciences' website under Investors at . A replay of the webcasts will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit聽, and follow the company on , and .
(*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:
SOURCE Neurocrine Biosciences, Inc.
FAQ
When and where will Neurocrine Biosciences (NBIX) present at the Morgan Stanley Healthcare Conference 2025?
How can investors access Neurocrine Biosciences' (NBIX) conference presentations in September 2025?
What therapeutic areas does Neurocrine Biosciences (NBIX) focus on?
Which executives from Neurocrine Biosciences (NBIX) will present at the Cantor Global Healthcare Conference 2025?
